# Shandong New Time Pharmaceutical Co., LTD trials: 35 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 35 trials with Shandong New Time Pharmaceutical Co., LTD as lead sponsor, 12 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Shandong New Time Pharmaceutical Co., LTD: 35 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/shandong-new-time-pharmaceutical-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 35
- Recruiting or not yet: 12
- Read on: November 19, 2026

## Trials

The 25 newest of 35, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 21, 2026 | NCT07829614 | F182112 Phase Ib Clinical Study for the Treatment of Patients With Systemic Lupus Erythematosus | Shandong New Time Pharmaceutical Co., LTD | Phase 1 | Recruiting | Systemic Lupus Erythematosus (SLE) | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07829614) |
| August 12, 2026 | NCT07761429 | A Phase II/III Study of F520 Combined With Paclitaxel Plus Carboplatin in the Treatment of Cancer of Unknown Primary (CUP) | Shandong New Time Pharmaceutical Co., LTD | Phase 2/3 | Recruiting | Cancer of Unknown Primary Site | 402 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07761429) |
| June 22, 2026 | NCT07661797 | Phase I Clinical Study of LNF2105 in Patients With Advanced Solid Tumors | Shandong New Time Pharmaceutical Co., LTD | Phase 1 | Not yet recruiting | Patients With Advanced Solid Tumors | 294 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07661797) |
| May 12, 2026 | NCT07579234 | A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety... | Shandong New Time Pharmaceutical Co., LTD | Phase 3 | Recruiting | Relapsed or Refractory Multiple Myeloma (RRMM) | 261 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07579234) |
| March 25, 2026 | NCT07492173 | Bioequivalence Study of Trifluridine and Tipiracil Hydrochloride Tablets on Fasting and Fed in Humans | Shandong New Time Pharmaceutical Co., LTD | Not applicable | Completed | Solid Tumor Cancer | 76 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07492173) |
| March 17, 2026 | NCT07478133 | Bioequivalence Study of Nalfurafine Hydrochloride Orally Disintegrating Tablets on Fasting and Fed in Humans | Shandong New Time Pharmaceutical Co., LTD | Not applicable | Completed | Pruritus | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07478133) |
| February 9, 2026 | NCT07396519 | Bioequivalence Study of Dronedarone Hydrochloride Tablets | Shandong New Time Pharmaceutical Co., LTD | Not applicable | Completed | Atrial Fibrillation (AF) | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07396519) |
| February 9, 2026 | NCT07396506 | Bioequivalence Study of Dronedarone Hydrochloride Tablets in Healthy Subjects Under Fasting Conditions | Shandong New Time Pharmaceutical Co., LTD | Not applicable | Completed | Atrial Fibrillation (AF) | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07396506) |
| December 31, 2025 | NCT07312188 | A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma | Shandong New Time Pharmaceutical Co., LTD | Phase 2 | Recruiting | Relapsed or Refractory Multiple Myeloma | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07312188) |
| July 1, 2025 | NCT07046273 | Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic® in Patients With Type 2 Diabetes | Shandong New Time Pharmaceutical Co., LTD | Phase 3 | Not yet recruiting | Type 2 Diabetes (T2DM) | 496 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07046273) |
| March 7, 2025 | NCT06863987 | A Phase III Clinical Study of Valsartan Oral Solution for the Treatment of Hypertension in Children and Adolescents | Shandong New Time Pharmaceutical Co., LTD | Phase 3 | Enrolling by invitation | Essential Hypertension | 342 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06863987) |
| February 11, 2025 | NCT06819774 | Phase III Clinical Study of Cetirizine Hydrochloride Injection in Treatment of Acute Urticaria | Shandong New Time Pharmaceutical Co., LTD | Phase 3 | Recruiting | Acute Urticaria | 284 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06819774) |
| January 20, 2025 | NCT06783257 | Phase II Clinical Study of Vonorasan Fumarate Injection in the Treatment of Peptic Ulcer Bleeding | Shandong New Time Pharmaceutical Co., LTD | Phase 2 | Not yet recruiting | Peptic Ulcer Bleeding | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06783257) |
| January 20, 2025 | NCT06782594 | A Phase Ⅱ Study of Mosapride Citrate Injection in the Treatment of Postoperative Gastrointestinal Dysfunction | Shandong New Time Pharmaceutical Co., LTD | Phase 2 | Unknown | Postoperative Gastrointestinal Dysfunction | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06782594) |
| January 1, 2025 | NCT06755515 | A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic... | Shandong New Time Pharmaceutical Co., LTD | Phase 2/3 | Enrolling by invitation | Cervical Cancer | 510 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06755515) |
| December 30, 2024 | NCT06752447 | A Phase I Study OfLNF2007 Monotherapy in Patients with Advanced Solid Tumors | Shandong New Time Pharmaceutical Co., LTD | Phase 1 | Not yet recruiting | Advanced Solid Tumors (Phase 1) | 94 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06752447) |
| December 9, 2024 | NCT06722950 | Phase II Clinical Study of AC591 in Preventing Oxaliplatin-Induced Peripheral Neuropathy | Shandong New Time Pharmaceutical Co., LTD | Phase 2 | Not yet recruiting | Colorectal Adenoma | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06722950) |
| January 26, 2024 | NCT06226363 | Phase I Study of LNF1901 in Advanced Malignant Tumors | Shandong New Time Pharmaceutical Co., LTD | Phase 1 | Not yet recruiting | Advanced Malignant Tumors | 82 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06226363) |
| January 26, 2024 | NCT06226350 | A Phase Ⅱ Study of F520 in Patients With Cervical Carcinoma | Shandong New Time Pharmaceutical Co., LTD | Phase 2 | Completed | Cervical Cancer | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06226350) |
| January 16, 2024 | NCT06206915 | Phase I Study of XZ120 in Malignant Tumors | Shandong New Time Pharmaceutical Co., LTD | Phase 1 | Not yet recruiting | Advanced Malignancies | 123 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06206915) |
| January 11, 2024 | NCT06202456 | A Phase IV Study of Huazhi Rougan Granule in the Treatment of Non-alcoholic Simple Fatty Liver | Shandong New Time Pharmaceutical Co., LTD | Phase 4 | Completed | Efficacy and Safety | 2,007 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06202456) |
| January 3, 2024 | NCT06188611 | A Phase IV Study of Huazhi Rougan Granule | Shandong New Time Pharmaceutical Co., LTD | Phase 4 | Completed | A Phase IV Trial to Investigate the Efficacy and Safety of Huazhi Rougan Granule in the Treatment of Non-alcoholic... | 282 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06188611) |
| February 23, 2023 | NCT05741021 | A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung... | Shandong New Time Pharmaceutical Co., LTD | Phase 2 | Unknown | Non-small Cell Lung Cancer, NSCLC, PD-1 | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05741021) |
| February 22, 2023 | NCT05740215 | Efficacy and Safety Study of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid Tumors | Shandong New Time Pharmaceutical Co., LTD | Phase 1/2 | Unknown | Solid Tumors | 158 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05740215) |
| June 7, 2022 | NCT05408221 | the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular Carcinoma | Shandong New Time Pharmaceutical Co., LTD | Phase 2/3 | Unknown | Hepatocellular Carcinoma | 576 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05408221) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 8 |
| Phase 1/2 | 1 |
| Phase 2 | 10 |
| Phase 2/3 | 3 |
| Phase 3 | 6 |
| Phase 4 | 2 |
| Not applicable | 5 |

## By status

| Status | Trials |
| --- | --- |
| Unknown | 13 |
| Completed | 8 |
| Not yet recruiting | 7 |
| Recruiting | 5 |
| Enrolling by invitation | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Recurrence | 3 |
| Multiple Myeloma | 3 |
| Atrial Fibrillation | 2 |
| Uterine Cervical Neoplasms | 2 |
| Lupus Erythematosus, Systemic | 1 |
| Diabetes Mellitus, Type 2 | 1 |
| Osteoporosis | 1 |
| Neoplasms, Unknown Primary | 1 |
| Lymphoma, T-Cell, Peripheral | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
| Lymphoma | 1 |
| Essential Hypertension | 1 |
| Pruritus | 1 |
| Carcinoma, Hepatocellular | 1 |
| Peptic Ulcer Hemorrhage | 1 |
| Parkinson Disease 4, Autosomal Dominant Lewy Body | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Specialty schools in the United States](https://specstream.ai/data/businesses/specialty-schools/united-states)
- [Music schools in the United States](https://specstream.ai/data/businesses/music-schools/united-states)
- [Garage door companies in the United States](https://specstream.ai/data/businesses/garage-door-companies/united-states)
- [Caterers in the United States](https://specstream.ai/data/businesses/caterers/united-states)
- [Water softening equipment suppliers in the United States](https://specstream.ai/data/businesses/water-softening-equipment-suppliers/united-states)
